Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma.
about
Systemic Inflammatory Response Based on Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker in Bladder CancerPretreatment Neutrophil to Lymphocyte Ratio as a Prognostic Predictor of Urologic Tumors: A Systematic Review and Meta-AnalysisPrognostic value of preoperative plasma fibrinogen level and platelet-to-lymphocyte ratio (F-PLR) in patients with localized upper tract urothelial carcinoma.Preoperative serum pre-albumin as an independent prognostic indicator in patients with localized upper tract urothelial carcinoma after radical nephroureterectomyPrognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive modelDecreased pretreatment lymphocyte/monocyte ratio is associated with poor prognosis in stage Ib1-IIa cervical cancer patients who undergo radical surgeryPretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancerIncreased neutrophil-to-lymphocyte ratio is associated with disease-specific mortality in patients with penile cancerNeutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsyNeutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomyPrognostic value of preoperative inflammatory response biomarkers in patients with sarcomatoid renal cell carcinoma and the establishment of a nomogram.Neutrophil/lymphocyte ratio has a prognostic value for patients with terminal cancerPeripheral platelet/lymphocyte ratio predicts lymph node metastasis and acts as a superior prognostic factor for cervical cancer when combined with neutrophil: Lymphocyte.Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy.Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy.Preoperative Lymphocyte-Monocyte Ratio Ameliorates the Accuracy of Differential Diagnosis in Non-Metastatic Infiltrative Renal Masses.Validation of the Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor in a Large Cohort of Chinese Patients with Upper Tract Urothelial Carcinoma.The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients.Pretreatment lymphocyte-monocyte ratio as a potential prognostic factor in a cohort of patients with upper tract urothelial carcinoma.Critical evaluation of the potential prognostic value of the pretreatment-derived neutrophil-lymphocyte ratio under consideration of C-reactive protein levels in clear cell renal cell carcinoma.Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: A multi-institutional study.Prognostic performance of inflammation-based prognostic indices in patients with resectable colorectal liver metastases.The systemic inflammation-based Glasgow Prognostic Score as a powerful prognostic factor in patients with upper tract urothelial carcinoma.Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients.Clinical significance of prognosis using the neutrophil-lymphocyte ratio and erythrocyte sedimentation rate in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma.Editorial Comment to Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: A multi-institutional study.
P2860
Q26765951-47E3BEFF-B4D3-4EE9-8AA1-707B9E9B912BQ26786160-4308D687-9C78-4B2A-81E1-51EB785C2EF0Q33829643-01FF09D9-FB94-4CBD-BD9B-DB1CE56728ADQ33829648-BC0D953A-1D79-4C63-9610-BFD46D94654CQ35128731-31D6850D-E607-48FD-8460-8066742D2E46Q35743180-C217E797-B7F9-4E09-9258-C7D0B1D544A1Q35925423-A1331C79-2BC3-4D0C-A7D3-5CEDD822D615Q36069609-834B1115-9B0D-4CCE-9F47-03098691639BQ36544801-97492623-80CF-4036-A9A9-80FFD21F4B2CQ36654421-340649DF-E862-466B-889C-2503C11F918BQ36755754-E576010D-3AEA-459C-B28D-7B6FB11265A1Q36902920-44D1A6D1-9503-46E9-8A0B-A68B2D3B0DD3Q37175931-FCEFEBE7-5B4B-4A25-B011-08C1218AE2CBQ37378328-348840B2-EC5B-4CDA-BF7C-4E89542FAA42Q37584081-51EAAD53-006F-45C2-9AF3-B2DF07A08E06Q37622164-88663100-7257-40C4-96CD-B0C144A5C954Q38610684-2E0E150C-93D9-4527-9E32-BDD9B6C67392Q38980174-EF93CEB8-8F5E-4C93-BB67-244D86AFC077Q39042081-AAC8A479-C8EC-4989-89B2-FB1EC271ECDFQ39138898-432AC1F5-35EE-4F96-BB7A-4941286171FAQ41027611-E56002C8-162A-42E3-B063-E0EEEBB971C7Q41162196-1B8C589B-4965-4332-96FB-89B22AF380AEQ49172009-900E6052-FF8F-4724-B6D0-D1F29F236A03Q51723701-D2F31927-817F-48D4-8093-8AC4912B10D3Q53040560-9D68952D-4443-4129-868B-4B8BA59941C3Q53533473-7E69D145-E860-48FC-A881-194130D8A085
P2860
Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Validation of the pretreatment ...... er tract urothelial carcinoma.
@ast
Validation of the pretreatment ...... er tract urothelial carcinoma.
@en
type
label
Validation of the pretreatment ...... er tract urothelial carcinoma.
@ast
Validation of the pretreatment ...... er tract urothelial carcinoma.
@en
prefLabel
Validation of the pretreatment ...... er tract urothelial carcinoma.
@ast
Validation of the pretreatment ...... er tract urothelial carcinoma.
@en
P2093
P2860
P356
P1476
Validation of the pretreatment ...... er tract urothelial carcinoma.
@en
P2093
G C Hutterer
J M Martín Hernández
R Zigeuner
S Mannweiler
T Stojakovic
P2860
P2888
P304
P356
10.1038/BJC.2014.180
P407
P577
2014-04-01T00:00:00Z
P6179
1020335843